Danish biotech finds new treatment for lung bleedings.
The Danish biotech company, Serendex, files use-patents on well known already approved and marketed drugs in new indications - drug repositioning - for treatment of critical ill patients.
- Serendex has discovered a more effective treatment for bleedings in the lung. By inhaling the Factor VII-protein instead of injecting it, the patient retrieves a more effective treatment, Kaare Fiala explains.
Kaare Fiala is current CEO of Serendex and other biotech companies such as Pharmaorigin and Drugrecure.
Learn more @ http://serendex.com
By Martin Kubert, email@example.com